Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 2.48% | 148.38 | 0.0% | $1836.76m | |
| NVAX | Novavax, Inc. | -7.69% | 221.50 | 92.9% | $1384.95m | |
| OCGN | Ocugen, Inc. | -10.41% | 8.00 | 0.0% | $863.06m | |
| AMGN | Amgen, Inc. | -1.07% | 227.52 | 1.3% | $600.44m | |
| ILMN | Illumina, Inc. | -3.30% | 445.86 | 3.5% | $554.99m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.18% | 453.19 | 2.7% | $531.63m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.87% | 212.98 | 1.9% | $510.83m | |
| GILD | Gilead Sciences, Inc. | -1.44% | 62.79 | 1.0% | $494.89m | |
| BNGO | BioNano Genomics, Inc. | -10.46% | 10.02 | 0.0% | $406.61m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.54% | 153.65 | 2.0% | $384.96m | |
| BIIB | Biogen, Inc. | -1.94% | 277.26 | 1.7% | $380.46m | |
| CRSP | CRISPR Therapeutics AG | -4.67% | 127.28 | 0.6% | $301.95m | |
| EXAS | EXACT Sciences Corp. | -2.61% | 131.30 | 18.4% | $246.20m | |
| SRNE | Sorrento Therapeutics, Inc. | -7.75% | 10.12 | 1.3% | $239.74m | |
| VXRT | Vaxart, Inc. | 2.18% | 7.50 | 0.0% | $224.09m |
Company Profile
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.